Using Dry Dispersion Laser Diffraction to Assess Dispersibility in Spheronized Agglomerate Formulations.

In this study, dry dispersion laser diffraction was used to study the dispersibility of spheronized agglomerate formulations and identify geometric particle size metrics that correlated well with aerodynamic particle size distribution (APSD). Eleven unique batches of agglomerates were prepared for both laser diffraction and cascade impaction testing. Correlations between the particle size distribution (PSD) and aerodynamic particle size distribution (APSD) metrics for the eleven agglomerate batches were determined in a semi-empirical manner. The strongest correlation between APSD and PSD was observed between the impactor-sized mass (%ISM) and the cumulative PSD fraction <14.5 µm. The strongest correlation with fine particle fraction (FPF) was observed with the cumulative PSD fraction <0.99 micron (R-squared = 0.974). In contrast to the other APSD metrics, good correlations were not found between the mass median aerodynamic diameter (MMAD) and the cumulative PSD fractions. Overall, the implementation of laser diffraction as a surrogate for cascade impaction has the potential to streamline product development. Laser diffraction measurements offer savings in labor and turnaround time compared to cascade impaction.

Photo-Oxidation Mechanisms in Liquid Pharmaceutical Formulations: The Overlooked Role of Singlet Oxygen Presented as a Case Study.

PURPOSE: Oxidation is one of the most common degradation pathways for active pharmaceutical ingredients (APIs) in pharmaceutical formulations, mostly involving 1-electron processes via peroxy radicals and 2-electron processes by peroxides. In liquid pharmaceutical formulations, several factors can impact oxidative instabilities including pH, excipient impurities, headspace oxygen, and the potential for photo-oxidation. Photo-oxidation can be particularly challenging to characterize given the number of oxidative mechanisms which can occur. This was observed during formulation development of a new chemical entity, MK-1454, where a degradation peak was observed during photostability studies which was not previously observed during peroxide and peroxyradical forced stress studies. METHODS: To gain a fundamental understanding of reactive oxygen species generation and its role in degradation of MK-1454, experiments were performed with materials which either generate or measure reactive oxygen species including organic hydroperoxides, singlet oxygen, and superoxide to fundamentally understand a photodegradation mechanism which was observed in the original formulation. LC-MS experiments further elucidated the structure and mechanism of this observed degradation pathway. RESULTS: A clear relationship between the decrease in dissolved oxygen after light exposure and the loss of MK-1454 was established. The data indicate that singlet oxygen is the most likely contributor of a particular photodegradation product. The singlet oxygen was generated by the inactive ingredients in the formulation, and LC-MS confirm this as the most likely pathway. CONCLUSION: This work highlights the importance of understanding photochemical degradation of APIs in solution formulations and provides approaches which can better elucidate those mechanisms and thereby control strategies.

Inhibition of N-Nitrosamine Formation in Drug Products: A Model Study.

Nitrosamines, in the absence of toxicological data, are regarded as potential mutagens and need to be controlled at nanogram levels in drug products. Recent high profile product withdrawals have increased regulatory scrutiny of nitrosamine formation assessments for marketed products and for new drug applications. Formation of nitrosamine in drug product is possible when nitrite and vulnerable amines are present. Nitrite is often present as an impurity in excipients at ppm levels, whereas vulnerable amines, if present, stem mainly from the drug substance or its major impurities. In the event a drug product were to contain a major source of vulnerable amines (such as a moiety in the drug substance), it would be desirable to have an inhibitor which could be added to the formulation to minimize nitrosamine formation.  This work demonstrates, for the first time, that the inhibition of nitrosamine formation in oral solid dosage forms is indeed feasible with suitable inhibitors. Five inhibitors investigated (ascorbic acid, sodium ascorbate, α-tocopherol, caffeic acid, and ferulic acid) showed >80% inhibition when spiked at ∼1 wt% level. This work has also shown the potential use of amino acids (glycine, lysine, histidine) as inhibitors of nitrosamine formation in solution.

Reduction-induced CO dissociation by a [Mn(bpy)(CO)4][SbF6] complex and its relevance in electrocatalytic CO2 reduction.

[Mn(bpy)(CO)3Br] is recognized as a benchmark electrocatalyst for CO2 reduction to CO, with the doubly reduced [Mn(bpy)(CO)3]- proposed to be the active species in the catalytic mechanism. The reaction of this intermediate with CO2 and two protons is expected to produce the tetracarbonyl cation, [Mn(bpy)(CO)4]+, thereby closing the catalytic cycle. However, this species has not been experimentally observed. In this study, [Mn(bpy)(CO)4][SbF6] (1) was directly synthesized and found to be an efficient electrocatalyst for the reduction of CO2 to CO in the presence of H2O. Complex 1 was characterized using X-ray crystallography as well as IR and UV-Vis spectroscopy. The redox activity of 1 was determined using cyclic voltammetry and compared with that of benchmark manganese complexes, e.g., [Mn(bpy)(CO)3Br] (2) and [Mn(bpy)(CO)3(MeCN)][PF6] (3). Infrared spectroscopic analyses indicated that CO dissociation occurs after a single-electron reduction of complex 1, producing a [Mn(bpy)(CO)3(MeCN)]+ species. Complex 1 was experimentally verified as both a precatalyst and an on-cycle intermediate in homogeneous Mn-based electrocatalytic CO2 reduction.

Elucidating the origins of enhanced CO2 reduction in manganese electrocatalysts bearing pendant hydrogen-bond donors.

Complexes of the general form [Mn(X)(CO)3bpy] (X = a variety of monodentate ligands, bpy = 2,2'-bipyridine) have been reported to act as electrocatalysts for the reduction of CO2 to CO. In this work, a series of phenol and anisole substituted bipyridine ligands were synthesized and ligated to a manganese metal center in order to probe for an intramolecular hydrogen-bonding interaction in the transition state of CO2 reduction. Ligands without the ability to intramolecularly hydrogen bond displayed decreased catalytic current density compared to those with the ability to hydrogen bond with CO2. Electrocatalysis was studied by performing voltammetric and bulk electrolysis experiments under argon or CO2 environments. Measurements of catalytic rates using hydrogen vs. deuterium for the intramolecular H/D-bonding step show that there is an isotope effect associated with the catalysis. The data presented herein suggest a mechanism involving two subsequent equilibrium isotope effects in combination with a primary kinetic isotope effect.

A cyanide-bridged di-manganese carbonyl complex that photochemically reduces CO2 to CO.

Manganese(i) tricarbonyl complexes such as [Mn(bpy)(CO)3L] (L = Br, or CN) are known to be electrocatalysts for CO2 reduction to CO. However, due to their rapid photodegradation under UV and visible light, these monomeric manganese complexes have not been considered as photocatalysts for CO2 reduction without the use of a photosensitizer. In this paper, we report a cyanide-bridged di-manganese complex, {[Mn(bpy)(CO)3]2(µ-CN)}ClO4, which is both electrocatalytic and photochemically active for CO2 reduction to CO. Compared to the [Mn(bpy)(CO)3CN] electrocatalyst, our CN-bridged binuclear complex is a more efficient electrocatalyst for CO2 reduction using H2O as a proton source. In addition, we report a photochemical CO2 reduction to CO using the dimanganese complex under 395 nm irradiation.